Follow Us:
Monday, February 17, 2020

Three-drug combo improves survival period of bowel cancer patients: Study

The data from the results of a phase-3 clinical trial noted that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal cancer who have a BRAF gene flaw.

By: Lifestyle Desk | New Delhi | Updated: July 8, 2019 7:37:25 am
bowel cancer, bowel cancer symptoms, bowel cancer care, bowel cancer treatment, bowel cancer news, bowel cancer new study, latest bowel cancer research, indianexpress.com, indianexpressonline, indianexpress, indianexpressnews, clinical trials bowel cancer, bowel cancer current treatment, bowel cancer india, survival period bowel cancer, what is bowel cancer, tumour biology, BRAF-mutated colorectal cancer, BRAF-mutated colorectal cancer news, chemotherapy for patients, metastatic colorectal cancer, colorectal cancer chemo, advanced bowel cancer patients news, Metastatic cancer symptoms, Metastatic cancer organs, Metastatic cancer spread, Metastatic cancer new research, Metastatic cancer can spread from one organ to another. (Source: Getty Images/Thinkstock)

A targetted three-drug combination therapy could increase the survival period of patients with advanced bowel cancer for overall nine months as compared to 5.4 months as per the current standard-of-care treatment, suggested a study.

The data from the results of a phase-3 clinical trial noted that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal cancer who have a BRAF gene flaw. Notably, metastatic cancer can spread from one organ to another.

The clinical trial involved 665 metastatic colorectal cancer patients with BRAF mutation.

BRAF mutations are estimated to occur in up to 15 per cent of patients with metastatic colorectal cancer, with V600E being the most common BRAF mutation and representing a poor prognosis for these patients.

ALSO READ: How gut bacteria, broccoli can help keep bowel cancer away

“This study builds on a decade of research into the tumour biology of BRAF-mutated colorectal cancer, and reflects a rationale combination to address the vulnerabilities unique to this tumour,” said principal investigator Scott Kopetz, associate professor at the University of Texas MD Anderson Cancer Center in the US.

“We are encouraged to see a meaningful improvement in outcomes with this new regimen for our patients,” Kopetz added.

Kopetz explained that the three-drug combination builds on growing understanding of the activation of cancer genes such as BRAF and the effects of targeted therapies. “Colorectal cancer does not respond to BRAF therapy alone because tumour cells adapt through other mechanisms after initial treatment. With this triple targeted therapy, we are using a very scientifically logical combination to inhibit BRAF and these other mechanisms,” he pointed out.

ALSO READ: Sunshine vitamin D boosts survival chances in bowel cancer

The international study was a multi-institutional collaboration with over 200 centres worldwide.

The findings were presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2019 in Barcelona, Spain.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

Advertisement
Advertisement
Advertisement
Advertisement